However, CCNE1 amplification has little relationship with human epidermal growth factor receptor 2 (HER2)-positive breast cancer prognosis and anti-HER2 targeted therapy efficacy (Luhtala et al., 2016). This evidence concerns the gene ERBB2 and breast carcinoma.